Axsome Therapeutics, Inc. vs Galapagos NV: SG&A Expense Trends

SG&A Expense Trends: Axsome Therapeutics, Inc. vs Galapagos NV

In the dynamic world of biotechnology, understanding financial trends is crucial. Over the past decade, Axsome Therapeutics, Inc. and Galapagos NV have shown distinct trajectories in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Axsome's SG&A expenses skyrocketed by over 23,000%, reflecting its aggressive growth strategy. In contrast, Galapagos NV experienced a more modest increase of approximately 940%, peaking in 2022.

Key Insights

• Axsome Therapeutics, Inc.: The company's SG&A expenses surged from a modest $1.4 million in 2014 to a staggering $323 million in 2023, indicating a strategic expansion and investment in operational capabilities.
• Galapagos NV: While starting at a higher base of $9 million in 2014, Galapagos saw its expenses peak at $239 million in 2022, before a notable decline in 2023.
  These trends highlight the contrasting financial strategies of these biotech giants, offering valuable insights for investors and industry analysts alike.